Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473414 | 0.91 | PKM (0.59) | PKMKDM4EPOLBLMNASMN1; SMN2 | |
| SCHEMBL2907457 | 0.89 | PKM (0.75) | PKMKDM4EPOLBLMNAUSP2 | |
| SCHEMBL5962801 | 0.81 | PKM (0.58) | PKMKDM4EPOLBLMNAUSP2 | |
| SCHEMBL5962841 | 0.81 | PKM (0.58) | PKMKDM4EPOLBLMNAUSP2 | |
| SCHEMBL23412396 | 0.80 | PKM (0.57) | PKMKDM4EPOLBLMNAUSP2 | |
| SCHEMBL5962774 | 0.78 | PKM (0.56) | PKMKDM4EPOLBLMNASMN1; SMN2 | |
| SCHEMBL3470106 | 0.78 | KDM4E (0.77) | PKMKDM4EPOLBUSP2HSD17B10 | |
| SCHEMBL268659 | 0.77 | TDP1 (0.42) | PKMLMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL890810 | 0.76 | PKM (1.00) | PKMKDM4EPOLBLMNAUSP2 | |
| SCHEMBL6383566 | 0.76 | HTT (0.59) | PKMPOLBLMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746242-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | OMEGA CO LTD | 2012-10-24 | — | — | CN | claimed |
| CN-102746242-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | OMEGA CO LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-101863844-B | Synthesis method of 6, 7-substituent-4-aniline quinazoline | XIANGZHEN BIOLOGY TECHNOLOGY CO LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20100267949-A1 | Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline | OMEGA MEDICAL TAIWAN LIMITED (TW) | 2010-10-21 | — | — | US | disclosed |
| CN-101863844-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | XIANGZHEN BIOLOGY TECHNOLOGY CO LTD | 2010-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267949-A1 | Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline | NQO2, ATIC, CYP3A7 | PKM 2624/4885KDM4E 2145/4885POLB 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.